US4401820A
(en)
|
1981-01-23 |
1983-08-30 |
Tanabe Seiyaku Co., Ltd. |
Process for racemizing optically active α-amino acids or a salt thereof
|
US4816567A
(en)
|
1983-04-08 |
1989-03-28 |
Genentech, Inc. |
Recombinant immunoglobin preparations
|
ATE117434T1
(de)
|
1988-03-30 |
1995-02-15 |
Toray Industries |
Gefriergetrocknete zusammensetzung, die ein mit meerrettichperoxydase markiertes fab'-fragment eines gegen menschliches beta-interferon gerichteten antikörpers und trehalose enthält; eia kit, der diese zusammensetzung enthält.
|
JPH03504605A
(ja)
|
1988-05-27 |
1991-10-09 |
セントカー・インコーポレーテツド |
抗体産生物の凍結乾燥した配合物
|
AU686113B2
(en)
|
1992-09-16 |
1998-02-05 |
Scripps Research Institute, The |
Human neutralizing monoclonal antibodies to respiratory syncytial virus
|
US6267958B1
(en)
|
1995-07-27 |
2001-07-31 |
Genentech, Inc. |
Protein formulation
|
MX9800684A
(es)
|
1995-07-27 |
1998-04-30 |
Genentech Inc |
Formulacion de proteinas liofilizadas isotonicas estables.
|
EP0851924A1
(en)
|
1995-09-18 |
1998-07-08 |
Intracel Corporation |
Neutralizing monoclonal antibodies to respiratory syncytial virus
|
US7365166B2
(en)
|
1997-04-07 |
2008-04-29 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US6171586B1
(en)
|
1997-06-13 |
2001-01-09 |
Genentech, Inc. |
Antibody formulation
|
HK1044159A1
(zh)
|
1998-12-01 |
2002-10-11 |
蛋白质设计实验室股份有限公司 |
抗γ-干扰素的人化抗体
|
ATE365052T1
(de)
|
1999-02-22 |
2007-07-15 |
Univ Connecticut |
Neue albuminfreie faktor viii formulierungen
|
CA2366706A1
(en)
|
1999-03-11 |
2000-09-14 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
WO2001018051A2
(en)
|
1999-09-09 |
2001-03-15 |
Schering Corporation |
Mammalian interleukin-12 p40 and interleukin b30, combinations thereof, antibodies, uses in pharmaceutical compositions
|
US7090847B1
(en)
|
1999-09-09 |
2006-08-15 |
Schering Corporation |
Mammalian cytokines; related reagents and methods
|
JP2003527334A
(ja)
*
|
1999-10-22 |
2003-09-16 |
ルードヴィッヒ インスティテュート フォー キャンサー リサーチ |
A33抗原特異的免疫グロブリン産物を用いるa33抗原を発現する癌の影響を低減する方法
|
US20050175986A1
(en)
|
2000-05-09 |
2005-08-11 |
Smit Kline Beecham Corporation |
Human monoclonal antibody
|
US8703126B2
(en)
|
2000-10-12 |
2014-04-22 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
EP2116265B1
(en)
|
2000-10-12 |
2020-12-23 |
Genentech, Inc. |
Reduced-viscosity concentrated protein formulations
|
US6818216B2
(en)
|
2000-11-28 |
2004-11-16 |
Medimmune, Inc. |
Anti-RSV antibodies
|
KR20100031769A
(ko)
|
2000-12-28 |
2010-03-24 |
알투스 파마슈티컬스 인코포레이티드 |
전항체 및 이의 단편의 결정과 이의 제조 및 사용 방법
|
EP1801123A3
(en)
|
2000-12-28 |
2007-11-21 |
Altus Pharmaceuticals Inc. |
Crystals of whole antibodies and fragments thereof and methods for making and using them
|
GB0113179D0
(en)
|
2001-05-31 |
2001-07-25 |
Novartis Ag |
Organic compounds
|
IL159475A0
(en)
|
2001-06-21 |
2004-06-01 |
Altus Biologics Inc |
Spherical protein particles, compositions containing the same and methods for the production thereof
|
ATE464068T1
(de)
|
2001-06-26 |
2010-04-15 |
Amgen Fremont Inc |
Antikörper gegen opgl
|
JP4317010B2
(ja)
|
2001-07-25 |
2009-08-19 |
ピーディーエル バイオファーマ,インコーポレイティド |
IgG抗体の安定な凍結乾燥医薬製剤
|
US20030138417A1
(en)
|
2001-11-08 |
2003-07-24 |
Kaisheva Elizabet A. |
Stable liquid pharmaceutical formulation of IgG antibodies
|
DE10207178A1
(de)
|
2002-02-19 |
2003-09-04 |
Novosom Ag |
Komponenten für die Herstellung amphoterer Liposomen
|
CA2476934C
(en)
|
2002-02-27 |
2009-06-16 |
Immunex Corporation |
Stabilized tnfr-fc composition comprising arginine
|
US20070134247A9
(en)
|
2002-04-12 |
2007-06-14 |
Ramot At Tel Aviv University Ltd. |
Prevention of brain inflammation as a result of induced autoimmune response
|
US7132100B2
(en)
|
2002-06-14 |
2006-11-07 |
Medimmune, Inc. |
Stabilized liquid anti-RSV antibody formulations
|
HUE065675T2
(hu)
|
2002-07-03 |
2024-06-28 |
Ono Pharmaceutical Co |
PD-L1 elleni antitesteket tartalmazó immunpotenciáló készítmények
|
CA2492143A1
(en)
|
2002-07-12 |
2004-01-22 |
Medarex, Inc. |
Methods and compositions for preventing oxidative degradation of proteins
|
US20040033228A1
(en)
|
2002-08-16 |
2004-02-19 |
Hans-Juergen Krause |
Formulation of human antibodies for treating TNF-alpha associated disorders
|
AU2003265511A1
(en)
|
2002-08-21 |
2004-03-11 |
Pharmacia Corporation |
Injectable pharmaceutical suspension in a two-chamber vial
|
WO2004019861A2
(en)
|
2002-08-28 |
2004-03-11 |
Pharmacia Corporation |
Stable ph optimized formulation of a modified antibody
|
WO2004055164A2
(en)
|
2002-12-13 |
2004-07-01 |
Abgenix, Inc. |
System and method for stabilizing antibodies with histidine
|
WO2004056875A1
(en)
|
2002-12-23 |
2004-07-08 |
Wyeth |
Antibodies against pd-1 and uses therefor
|
EP2270051B1
(en)
|
2003-01-23 |
2019-05-15 |
Ono Pharmaceutical Co., Ltd. |
Antibody specific for human PD-1 and CD3
|
US20040219150A1
(en)
|
2003-02-06 |
2004-11-04 |
Cua Daniel J. |
Uses of mammalian cytokine; related reagents
|
KR20050110628A
(ko)
|
2003-02-10 |
2005-11-23 |
엘란 파마슈티칼스, 인크. |
면역글로불린 제제 및 이의 제조방법
|
CL2004000467A1
(es)
|
2003-03-10 |
2005-05-06 |
Schering Corp |
Uso de un anticuerpo contra la subunidad p19 de interleuquina 23 (il-23), para preparar una composicion para el tratamiento de cnacer o de tumores. ]
|
CN102258464A
(zh)
|
2003-04-04 |
2011-11-30 |
健泰科生物技术公司 |
高浓度抗体和蛋白制剂
|
AU2004247015B2
(en)
|
2003-05-14 |
2010-12-16 |
Immunogen, Inc. |
Drug conjugate composition
|
WO2005035574A1
(ja)
|
2003-10-09 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
IgM高濃度安定化溶液
|
US8277810B2
(en)
|
2003-11-04 |
2012-10-02 |
Novartis Vaccines & Diagnostics, Inc. |
Antagonist anti-CD40 antibodies
|
PE20090046A1
(es)
|
2003-11-10 |
2009-01-26 |
Schering Corp |
Anticuerpo recombinante humanizado anti-interleuquina 10
|
DE10355904A1
(de)
|
2003-11-29 |
2005-06-30 |
Merck Patent Gmbh |
Feste Formen von anti-EGFR-Antikörpern
|
EP1712240B1
(en)
|
2003-12-25 |
2015-09-09 |
Kyowa Hakko Kirin Co., Ltd. |
Stable water-based medicinal preparation containing antibody
|
HUE026132T2
(en)
|
2004-01-07 |
2016-05-30 |
Novartis Vaccines & Diagnostics Inc |
M-CSF-specific monoclonal antibody and its uses
|
KR20120089307A
(ko)
|
2004-02-12 |
2012-08-09 |
메르크 파텐트 게엠베하 |
항-egfr 항체들의 고농축 액체 제형물
|
ATE533502T1
(de)
|
2004-02-17 |
2011-12-15 |
Schering Corp |
Verfahren zur modulation der il-23-aktivität; relevante reagenzien
|
JP4857259B2
(ja)
|
2004-03-24 |
2012-01-18 |
アボット バイオセラピューティクス コーポレイション |
癌細胞増殖を阻害するための抗α5β1抗体の使用
|
EP1755673B1
(en)
|
2004-04-12 |
2014-07-23 |
MedImmune, LLC |
Anti-il-9 antibody formulations and uses thereof
|
ATE476993T1
(de)
|
2004-06-07 |
2010-08-15 |
Univ Ramot |
Verfahren zur passiven immunisierung gegen eine durch amyloidaggregation gekennzeichnete krankheit oder erkrankung mit vermindertem nervenentzündungsrisiko
|
AR049390A1
(es)
|
2004-06-09 |
2006-07-26 |
Wyeth Corp |
Anticuerpos contra la interleuquina-13 humana y usos de los mismos
|
EP2298807A3
(en)
|
2004-07-30 |
2011-05-18 |
Rinat Neuroscience Corp. |
Antibodies directed against amyloid-beta peptide and methods using same
|
JO3000B1
(ar)
|
2004-10-20 |
2016-09-05 |
Genentech Inc |
مركبات أجسام مضادة .
|
US20080057070A1
(en)
|
2004-11-04 |
2008-03-06 |
Chiron Corporation |
Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
|
GT200600031A
(es)
|
2005-01-28 |
2006-08-29 |
|
Formulacion anticuerpo anti a beta
|
PE20061201A1
(es)
|
2005-01-28 |
2006-11-03 |
Wyeth Corp |
Formulaciones liquidas estabilizadas de polipeptido
|
DOP2006000029A
(es)
|
2005-02-07 |
2006-08-15 |
Genentech Inc |
Antibody variants and uses thereof. (variantes de un anticuerpo y usos de las mismas)
|
TW200719913A
(en)
|
2005-03-08 |
2007-06-01 |
Pharmacia & Upjohn Co Llc |
Anti-madcam antibody compositions
|
US7785595B2
(en)
|
2005-04-18 |
2010-08-31 |
Yeda Research And Development Company Limited |
Stabilized anti-hepatitis B (HBV) antibody formulations
|
ES2361269T3
(es)
|
2005-04-22 |
2011-06-15 |
Eli Lilly And Company |
Anticuerpos especificos de tgf beta 1.
|
NZ563193A
(en)
|
2005-05-09 |
2010-05-28 |
Ono Pharmaceutical Co |
Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
|
BRPI0611765B1
(pt)
|
2005-06-07 |
2022-09-27 |
Esbatech Ag |
Anticorpo ou fragmento de anticorpo estável e solúvel que se liga especificamente ao tnf-alfa seus usos e composição diagnóstica ou terapêutica
|
EP1896505A2
(en)
|
2005-06-15 |
2008-03-12 |
Schering Corporation |
Anti-igf1r antibody formulations
|
SI1896073T1
(sl)
|
2005-06-30 |
2013-06-28 |
Janssen Biotech, Inc. |
Protitelesa proti il-23, sestavki, prostopki in uporabe
|
MX2008001068A
(es)
|
2005-07-29 |
2008-03-19 |
Amgen Inc |
Formulacion que inhibe la agregacion de proteina.
|
NZ599176A
(en)
|
2005-08-03 |
2014-04-30 |
Immunogen Inc |
Immunoconjugate formulations
|
KR101028200B1
(ko)
|
2005-08-25 |
2011-04-11 |
일라이 릴리 앤드 캄파니 |
항-il-23 항체
|
HUE032131T2
(en)
|
2005-08-31 |
2017-09-28 |
Merck Sharp & Dohme |
Constructed anti-IL-23 antibodies
|
US20070065437A1
(en)
|
2005-09-12 |
2007-03-22 |
Greg Elson |
Anti-CD3 antibody formulations
|
SI1942939T2
(sl)
|
2005-09-30 |
2021-11-30 |
Medimmune Limited |
Sestavek protitelesa proti interlevkinu-13
|
JP5231810B2
(ja)
|
2005-12-28 |
2013-07-10 |
中外製薬株式会社 |
抗体含有安定化製剤
|
BRPI0620946B8
(pt)
|
2005-12-29 |
2021-05-25 |
Centocor Inc |
anticorpo il-23p19 isolado, composição, método in vitro, artigo de fabricação, molécula e vetor de ácido nucleico, célula hospedeira procariótica
|
EP1988922A4
(en)
|
2006-02-03 |
2010-06-02 |
Medimmune Llc |
PROTEIN FORMULATIONS
|
WO2007110339A1
(en)
|
2006-03-28 |
2007-10-04 |
F. Hoffmann-La Roche Ag |
Anti-igf-1r human monoclonal antibody formulation
|
EP2021030A2
(en)
|
2006-04-21 |
2009-02-11 |
Amgen, Inc. |
Buffering agents for biopharmaceutical formulations
|
BRPI0710826A2
(pt)
|
2006-04-21 |
2011-08-23 |
Novartis Ag |
composições farmacêuticas de anticorpo anti-cd40 antagonista
|
CA2655372A1
(en)
|
2006-06-13 |
2007-12-21 |
Zymogenetics, Inc. |
Il-17 and il-23 antagonists and methods of using the same
|
PE20081179A1
(es)
|
2006-10-06 |
2008-09-29 |
Amgen Inc |
Formulaciones estables de anticuerpos egfr
|
ES2925992T3
(es)
|
2006-10-20 |
2022-10-20 |
Amgen Inc |
Formulaciones estables de polipéptidos
|
WO2008057240A2
(en)
|
2006-10-27 |
2008-05-15 |
Abbott Biotechnology Ltd. |
Crystalline anti-htnfalpha antibodies
|
EP2088997B1
(en)
|
2006-12-05 |
2016-08-24 |
Janssen Vaccines & Prevention B.V. |
Liquid anti-rabies antibody formulations
|
WO2008076321A1
(en)
|
2006-12-14 |
2008-06-26 |
Schering Corporation |
Engineered anti-tslp antibody
|
WO2008079290A2
(en)
|
2006-12-21 |
2008-07-03 |
Amgen Inc |
Stable buffered formulations containing polypeptides
|
PE20081610A1
(es)
|
2007-01-09 |
2008-12-09 |
Wyeth Corp |
Formulaciones de anticuerpos anti-il-13 y usos de los mismos
|
TWI426918B
(zh)
|
2007-02-12 |
2014-02-21 |
Merck Sharp & Dohme |
Il-23拮抗劑於治療感染之用途
|
MX2009009079A
(es)
|
2007-02-23 |
2009-08-31 |
Schering Corp |
Anticuerpos anti-il-23p19 de ingenieria.
|
CA2678863A1
(en)
|
2007-02-23 |
2008-08-28 |
Schering Corporation |
Engineered anti-il-23p19 antibodies
|
NZ598881A
(en)
|
2007-03-29 |
2013-11-29 |
Abbvie Inc |
Crystalline anti-human il-12 antibodies
|
CA2682292A1
(en)
|
2007-03-30 |
2008-10-09 |
Medimmune, Llc |
Aqueous formulation comprising an anti-human interferon alpha antibody
|
US20090208492A1
(en)
|
2007-06-14 |
2009-08-20 |
Elan Pharmaceuticals, Inc. |
Lyophilized Immunoglobulin Formulations and Methods of Preparation
|
AR067011A1
(es)
|
2007-06-14 |
2009-09-30 |
Biogen Idec Inc |
Formulaciones de anticuerpos
|
KR101562580B1
(ko)
|
2007-06-18 |
2015-10-22 |
머크 샤프 앤 도메 비.브이. |
사람 프로그램된 사멸 수용체 pd-1에 대한 항체
|
AU2008269086B2
(en)
|
2007-06-25 |
2014-06-12 |
Amgen Inc. |
Compositions of specific binding agents to hepatocyte growth factor
|
UA107557C2
(xx)
|
2007-07-06 |
2015-01-26 |
|
Композиція антитіла офатумумабу
|
US20100286038A1
(en)
|
2007-09-21 |
2010-11-11 |
Valentyn Antochshuk |
Formulation containing cyclin-dependent kinase inhibiting compound and method of treating tumors using the same
|
EP2205276A4
(en)
|
2007-09-28 |
2012-08-15 |
Janssen Biotech Inc |
ANTI-IL-12 / 23P40 ANTIBODIES, EPITOPES, FORMULATIONS, COMPOSITIONS, METHODS AND USES
|
AR068723A1
(es)
|
2007-10-05 |
2009-12-02 |
Glaxo Group Ltd |
Proteina que se une a antigenos que se une a il-23 humana y sus usos
|
EP2225275A4
(en)
|
2007-11-28 |
2013-04-03 |
Medimmune Llc |
PROTEIN FORMULATION
|
UA101487C2
(en)
|
2007-12-21 |
2013-04-10 |
Ф. Хоффманн-Ля Рош Аг |
Humanized b-ly1 antibody formulation
|
PE20091174A1
(es)
|
2007-12-27 |
2009-08-03 |
Chugai Pharmaceutical Co Ltd |
Formulacion liquida con contenido de alta concentracion de anticuerpo
|
RU2470628C2
(ru)
|
2007-12-28 |
2012-12-27 |
Биоинвент Интернешнл Аб |
Состав
|
BRPI0908361A2
(pt)
|
2008-02-07 |
2015-04-07 |
Amgen Inc |
Seringas previamente cheias contendo composição e métodos de preparação das mesmas e de estabilização de agente de ligação específico em composição.
|
HUE034465T2
(en)
|
2008-02-11 |
2018-02-28 |
Cure Tech Ltd |
Monoclonal antibodies for tumor treatment
|
WO2009120684A1
(en)
|
2008-03-25 |
2009-10-01 |
Medimmune, Llc |
Antibody formulation
|
DK2279412T3
(en)
|
2008-04-09 |
2017-10-16 |
Genentech Inc |
PRESENT UNKNOWN COMPOSITIONS AND PROCEDURES FOR TREATING IMMUNRATED DISEASES
|
KR20110016958A
(ko)
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
JP5945096B2
(ja)
|
2008-07-04 |
2016-07-05 |
小野薬品工業株式会社 |
抗ヒトpd−1抗体の癌に対する治療効果を最適化するための判定マーカーの使用
|
AU2009288419B2
(en)
|
2008-08-27 |
2015-08-06 |
Merck Sharp & Dohme Llc |
Lyophilized formulatons of engineered anti-IL-23p19 antibodies
|
CA2736864C
(en)
|
2008-09-19 |
2020-10-13 |
Pfizer Inc. |
Stable liquid antibody formulation
|
EP4104821A1
(en)
|
2008-10-29 |
2022-12-21 |
Ablynx N.V. |
Formulations of single domain antigen binding molecules
|
WO2010062372A2
(en)
|
2008-11-03 |
2010-06-03 |
President And Fellows Of Harvard College |
Methods for modulating nf-kb using gibberellins
|
TW201021831A
(en)
|
2008-11-17 |
2010-06-16 |
Genentech Inc |
Method and formulation for reducing aggregation of a macromolecule under physiological conditions
|
WO2010069858A1
(en)
|
2008-12-19 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition
|
AR075715A1
(es)
|
2009-03-05 |
2011-04-20 |
Novartis Ag |
Formulacion de anticuerpo liofilizado
|
KR20110125664A
(ko)
|
2009-03-06 |
2011-11-21 |
메디뮨 엘엘씨 |
인간화된 항-cd19 항체 제형
|
WO2010102241A1
(en)
|
2009-03-06 |
2010-09-10 |
Genentech, Inc. |
Antibody formulation
|
EP2230312A1
(en)
|
2009-03-19 |
2010-09-22 |
Helmholtz-Zentrum für Infektionsforschung GmbH |
Probe compound for detecting and isolating enzymes and means and methods using the same
|
JP2012526121A
(ja)
|
2009-05-04 |
2012-10-25 |
アボツト・バイオテクノロジー・リミテツド |
ヒト抗tnfアルファ抗体の安定した高蛋白質濃度製剤
|
US9155745B2
(en)
|
2009-06-16 |
2015-10-13 |
Universite De Geneve |
Bevacizumab formulations with lower aggregation propensity, comprising corticosteroid anti-inflammatory drugs
|
US20120114646A1
(en)
|
2009-06-18 |
2012-05-10 |
Wyeth Llc |
Lyophilized formulations for small modular immunopharmaceuticals
|
EP2453874A2
(en)
|
2009-07-14 |
2012-05-23 |
Biogen Idec MA Inc. |
Methods for inhibiting yellow color and peroxide formation in a composition
|
WO2011017070A1
(en)
|
2009-07-28 |
2011-02-10 |
Merck Sharp & Dohme Corp. |
Methods for producing high concentration lyophilized pharmaceutical formulations
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
WO2011024862A1
(ja)
|
2009-08-31 |
2011-03-03 |
三洋化成工業株式会社 |
タンパク質水溶液の安定化剤、この安定化剤を含有するタンパク質水溶液及び液体洗剤組成物、並びに、この安定化剤を用いるタンパク質の安定化方法
|
KR101790802B1
(ko)
|
2009-09-03 |
2017-10-27 |
머크 샤프 앤드 돔 코포레이션 |
항-gitr 항체
|
US20110059079A1
(en)
|
2009-09-04 |
2011-03-10 |
Xoma Technology Ltd. |
Antibody Coformulations
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
ES2784123T3
(es)
|
2009-11-04 |
2020-09-22 |
Merck Sharp & Dohme |
Anticuerpo anti TSLP genomodificado
|
SG10201705886SA
(en)
|
2009-12-21 |
2017-08-30 |
Genentech Inc |
Antibody formulation
|
KR20120110175A
(ko)
|
2009-12-29 |
2012-10-09 |
에프. 호프만-라 로슈 아게 |
항체 제제
|
US20120294866A1
(en)
|
2010-01-19 |
2012-11-22 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for proteins
|
AR080428A1
(es)
|
2010-01-20 |
2012-04-11 |
Chugai Pharmaceutical Co Ltd |
Formulaciones liquidas estabilizadas contentivas de anticuerpos
|
AU2011227335B2
(en)
|
2010-03-17 |
2014-11-06 |
Abbott Research B.V. |
Anti-nerve growth factor (NGF) antibody compositions
|
EP2566510A1
(en)
|
2010-05-03 |
2013-03-13 |
F. Hoffmann-La Roche AG |
Compositions and methods useful for reducing the viscosity of protein-containing formulations
|
WO2011160024A2
(en)
|
2010-06-17 |
2011-12-22 |
Fuzians Biomedicals, Inc. |
Compounds useful as antiviral agents, compositions, and methods of use
|
EP2399604A1
(en)
|
2010-06-25 |
2011-12-28 |
F. Hoffmann-La Roche AG |
Novel antibody formulation
|
FR2962908A1
(fr)
|
2010-07-20 |
2012-01-27 |
Lfb Biotechnologies |
Formulation d'anticorps anti-cd20
|
WO2012018538A2
(en)
|
2010-07-26 |
2012-02-09 |
Schering Corporation |
Bioassays for determining pd-1 modulation
|
IL283424B2
(en)
|
2010-10-06 |
2023-09-01 |
Regeneron Pharma |
Stabilized formulations that include antibodies against the interleukin receptor (il-4r)
|
US9458240B2
(en)
|
2010-12-10 |
2016-10-04 |
Novartis Pharma Ag |
Anti-BAFFR antibody formulations
|
PE20140437A1
(es)
|
2011-03-25 |
2014-04-17 |
Amgen Inc |
Formulaciones de anticuerpos
|
MX341076B
(es)
|
2011-03-31 |
2016-08-04 |
Merck Sharp & Dohme |
Formulaciones estables de anticuerpos para el receptor humano pd-1 de meurte programada y tratamientos relacionados.
|
EA201391489A1
(ru)
|
2011-04-07 |
2014-02-28 |
ГЛЭКСОСМИТКЛАЙН ЭлЭлСи |
Композиции со сниженной вязкостью
|
UY34105A
(es)
|
2011-06-03 |
2012-07-31 |
Lg Life Sciences Ltd |
Formulación líquida estable de etanercept
|
US9574005B2
(en)
|
2011-07-19 |
2017-02-21 |
Chugai Seiyaku Kabushiki Kaisha |
Stable Protein-containing preparation containing argininamide or analogous compound thereof
|
AR087305A1
(es)
|
2011-07-28 |
2014-03-12 |
Regeneron Pharma |
Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
|
EP4074694A1
(en)
|
2011-10-27 |
2022-10-19 |
Massachusetts Institute Of Technology |
Amino acid-, peptide- an polypeptide-lipids, isomers, compositions, an uses thereof
|
KR102063028B1
(ko)
|
2012-01-23 |
2020-01-07 |
리제너론 파아마슈티컬스, 인크. |
항-ang2 항체를 함유하는 안정화된 제형
|
EP3412310B1
(en)
|
2012-03-07 |
2022-09-07 |
Cadila Healthcare Limited |
Pharmaceutical formulations of tnf-alpha antibodies
|
EP2834695B1
(en)
|
2012-04-03 |
2021-08-25 |
University Court of The University of St Andrews |
High resolution imaging of extended volumes
|
EP2844284A1
(en)
|
2012-05-03 |
2015-03-11 |
Boehringer Ingelheim International GmbH |
Anti-il-23p19 antibodies
|
US20140004131A1
(en)
|
2012-05-04 |
2014-01-02 |
Novartis Ag |
Antibody formulation
|
EP2866833B1
(en)
|
2012-06-27 |
2019-05-15 |
Merck Sharp & Dohme Corp. |
Crystalline anti-human il-23 antibodies
|
NZ701040A
(en)
|
2012-07-04 |
2017-02-24 |
Hoffmann La Roche |
Covalently linked antigen-antibody conjugates
|
FR2994390B1
(fr)
|
2012-08-10 |
2014-08-15 |
Adocia |
Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
|
US20140227250A1
(en)
|
2012-08-23 |
2014-08-14 |
Merck Sharp & Dohme Corp. |
Stable formulations of antibodies to tslp
|
US8883979B2
(en)
|
2012-08-31 |
2014-11-11 |
Bayer Healthcare Llc |
Anti-prolactin receptor antibody formulations
|
US9592297B2
(en)
|
2012-08-31 |
2017-03-14 |
Bayer Healthcare Llc |
Antibody and protein formulations
|
US9649383B2
(en)
|
2012-11-19 |
2017-05-16 |
Merck Sharp & Dohme Corp. |
Liquid formulations for TNFR:Fc fusion proteins
|
EP2931311A4
(en)
|
2012-12-13 |
2016-08-17 |
Merck Sharp & Dohme |
LYOPHILIZED BALLULAR PELLETS OF ANTI-IL-23 ANTIBODIES
|
US9700633B2
(en)
|
2013-01-28 |
2017-07-11 |
Jenkem Technology Co., Ltd., Tianjin Branch |
Conjugates of water soluble polymer-amino acid oligopeptide-drug, preparation method and use thereof
|
JP6463725B2
(ja)
|
2013-03-13 |
2019-02-06 |
シアトル ジェネティックス, インコーポレイテッド |
シクロデキストリンおよび抗体−薬物結合体製剤
|
BR112016001522B1
(pt)
|
2013-07-23 |
2019-10-01 |
Novaliq Gmbh |
Composições de anticorpo estabilizado
|
TWI649308B
(zh)
|
2013-07-24 |
2019-02-01 |
小野藥品工業股份有限公司 |
喹啉衍生物
|
IL312865B2
(en)
|
2013-09-11 |
2025-06-01 |
Eagle Biologics Inc |
Liquid protein formulations containing viscosity-lowering agents
|
HUE044730T2
(hu)
*
|
2013-09-20 |
2019-11-28 |
Bristol Myers Squibb Co |
Anti-LAG-3 antitestek és Anti-PD-1 antitestek kombinációja tumorok kezelésére
|
WO2015057541A1
(en)
|
2013-10-16 |
2015-04-23 |
Merck Sharp & Dohme Corp. |
Method of obtaining thermostable dried vaccine formulations
|
RU2589691C2
(ru)
|
2014-06-16 |
2016-07-10 |
Общество с ограниченной ответственностью "Промоген-МАТ" |
Стабильная композиция антитела, специфически связывающегося с her2 рецепторами, и способ ее получения
|
US20160074515A1
(en)
|
2014-06-20 |
2016-03-17 |
Reform Biologics, Llc |
Viscosity-reducing excipient compounds for protein formulations
|
CA2955612C
(en)
|
2014-07-18 |
2022-05-17 |
Advaxis, Inc. |
Combination of a pd-1 antagonist and a listeria-based vaccine for treating prostate cancer
|
CN105296433B
(zh)
|
2014-08-01 |
2018-02-09 |
中山康方生物医药有限公司 |
一种ctla4抗体、其药物组合物及其用途
|
RS63364B1
(sr)
|
2014-08-11 |
2022-07-29 |
Acerta Pharma Bv |
Terapeutske kombinacije btk inhibitora, pd-1 inhibitora i/ili pd-l1 inhibitora
|
JO3663B1
(ar)
*
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
AP2017009765A0
(en)
|
2014-08-19 |
2017-02-28 |
Merck Sharp & Dohme |
Anti-tigit antibodies
|
TR201907471T4
(tr)
|
2014-08-28 |
2019-06-21 |
Halozyme Inc |
Bir hiyalüronan ayrıştırıcı enzim ve bir bağışıklık kontrol noktası inhibitörüyle kombinasyon terapisi.
|
WO2016035006A1
(en)
|
2014-09-01 |
2016-03-10 |
Dr. Reddy’S Laboratories Limited |
Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
|
KR20170096112A
(ko)
|
2014-11-17 |
2017-08-23 |
제넨테크, 인크. |
Ox40 결합 효능제 및 pd-1 축 결합 길항제를 포함하는 조합 요법
|
WO2016100882A1
(en)
|
2014-12-19 |
2016-06-23 |
Novartis Ag |
Combination therapies
|
US20170360929A1
(en)
|
2014-12-23 |
2017-12-21 |
Pfizer Inc. |
Stable aqueous antibody formulation for anti tnf alpha antibodies
|
EA039219B1
(ru)
|
2014-12-23 |
2021-12-20 |
Бристол-Майерс Сквибб Компани |
Антитела к tigit
|
CA2971757A1
(en)
|
2015-01-20 |
2016-07-28 |
Immunexcite, Inc. |
Compositions and methods for cancer immunotherapy
|
AR103726A1
(es)
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
CA2978226A1
(en)
|
2015-03-04 |
2016-09-09 |
Merck Sharpe & Dohme Corp. |
Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
|
WO2016153839A1
(en)
|
2015-03-20 |
2016-09-29 |
Merck Sharp & Dohme Corp. |
Combination of a pd-1 antagonist and vorinostat for treating cancer
|
EP3770171A1
(en)
|
2015-04-03 |
2021-01-27 |
XOMA Technology Ltd. |
Treatment of cancer using inhibitors of tgf-beta and pd-1
|
CN120381515A
(zh)
|
2015-04-17 |
2025-07-29 |
百时美施贵宝公司 |
包含抗pd-1抗体和另外的抗体的组合的组合物
|
JP2018515474A
(ja)
|
2015-04-28 |
2018-06-14 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
抗pd−1抗体を使用するpd−l1陽性黒色腫の処置
|
EP3892284B1
(en)
*
|
2015-05-29 |
2024-05-22 |
Merck Sharp & Dohme LLC |
Combination of a pd-1 antagonist and a cpg-c type oligonucleotide for treating cancer
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
US9902772B2
(en)
|
2015-07-22 |
2018-02-27 |
Sorrento Therapeutics, Inc. |
Antibody therapeutics that bind LAG3
|
US20190010231A1
(en)
|
2015-08-07 |
2019-01-10 |
Pieris Pharmaceuticals Gmbh |
Novel fusion polypeptide specific for lag-3 and pd-1
|
WO2017030823A2
(en)
|
2015-08-14 |
2017-02-23 |
Merck Sharp & Dohme Corp. |
Anti-tigit antibodies
|
WO2017040864A1
(en)
|
2015-09-01 |
2017-03-09 |
First Wave Biopharma |
Methods and compositions for treating conditions associated with an abnormal inflammatory responses
|
MY205096A
(en)
|
2015-09-02 |
2024-10-01 |
Immutep Sas |
Anti-lag-3 antibodies
|
JP2018531914A
(ja)
|
2015-09-14 |
2018-11-01 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
CD155/TIGIT経路およびTGF−βのアンタゴニストを介してがんを処置するための組成物および方法
|
US9995753B2
(en)
|
2015-09-25 |
2018-06-12 |
Merck Sharp & Dohme Corp. |
Anti-pembrolizumab antibodies
|
US20170097333A1
(en)
|
2015-09-28 |
2017-04-06 |
Merck Sharp & Dohme Corp. |
Cell based assay to measure the t-cell stimulating capacity of anti-lag3 antibodies and other agents
|
RU2731418C2
(ru)
|
2015-09-28 |
2020-09-02 |
Сучжоу Санкадия Биофармасьютикалз Ко., Лтд. |
Стабильный фармацевтический препарат на основе антитела к pd-1 и его применение в медицине
|
WO2017059095A1
(en)
|
2015-10-01 |
2017-04-06 |
Potenza Therapeutics, Inc. |
Anti-tigit antigen-binding proteins and methods of use thereof
|
ES2924402T3
(es)
|
2015-10-02 |
2022-10-06 |
Symphogen As |
Anticuerpos anti-PD-1 y composiciones
|
JO3555B1
(ar)
|
2015-10-29 |
2020-07-05 |
Merck Sharp & Dohme |
جسم مضاد يبطل فعالية فيروس الالتهاب الرئوي البشري
|
EP4085929A1
(en)
|
2015-11-03 |
2022-11-09 |
Janssen Biotech, Inc. |
Subcutaneous formulations of anti-cd38 antibodies and their uses
|
US20190010224A1
(en)
|
2015-12-22 |
2019-01-10 |
Merck Sharp & Dohme Corp. |
Formulations of engineered anti-il-10 antibodies
|
DK3405490T3
(da)
|
2016-01-21 |
2022-01-10 |
Pfizer |
Mono- og bispecifikke antistoffer mod epidermal vækstfaktorreceptor variant iii og cd3 og anvendelser deraf
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
KR20220103806A
(ko)
*
|
2016-05-18 |
2022-07-22 |
베링거 인겔하임 인터내셔날 게엠베하 |
암 치료용 항-pd1 및 항-lag3 항체
|
JP7010854B2
(ja)
|
2016-06-14 |
2022-01-26 |
ゼンコア インコーポレイテッド |
二重特異性チェックポイント阻害剤抗体
|
WO2018091729A2
(en)
|
2016-11-21 |
2018-05-24 |
Zaklady Farmaceutyczne Polpharma Sa |
Aqueous pharmaceutical formulations
|
UA128200C2
(uk)
|
2016-12-23 |
2024-05-08 |
Серум Інстітьют Оф Індія Прайвет Лімітед |
Удосконалені способи підвищення продуктивності антитіл у культурах клітин ссавців і зведення до мінімуму агрегації у процесах виділення і очищення, одержання композицій та стабільні композиції антитіл, одержані цими способами
|
US20200283516A1
(en)
|
2017-03-01 |
2020-09-10 |
Medimmune Limited |
Formulations of monoclonal antibodies
|
TW202228779A
(zh)
|
2017-03-01 |
2022-08-01 |
英商梅迪繆思有限公司 |
抗rsv單株抗體配製物
|
US20210101980A1
(en)
|
2017-03-31 |
2021-04-08 |
Bristol-Myers Squibb Company |
Methods of treating tumor
|
US11603407B2
(en)
|
2017-04-06 |
2023-03-14 |
Regeneron Pharmaceuticals, Inc. |
Stable antibody formulation
|
US11845798B2
(en)
*
|
2017-05-02 |
2023-12-19 |
Merck Sharp & Dohme Llc |
Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
US20200354453A1
(en)
|
2017-05-02 |
2020-11-12 |
Merck Sharp & Dohme Corp. |
Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
JP2020518598A
(ja)
|
2017-05-02 |
2020-06-25 |
メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. |
単独およびプログラム死受容体1(pd−1)抗体と組み合わされた抗ctla4抗体の安定な製剤、ならびにその使用方法
|
WO2018222722A2
(en)
|
2017-05-30 |
2018-12-06 |
Bristol-Myers Squibb Company |
Compositions comprising an anti-lag-3 antibody or an anti-lag-3 antibody and an anti-pd-1 or anti-pd-l1 antibody
|
HUE065242T2
(hu)
*
|
2017-05-30 |
2024-05-28 |
Bristol Myers Squibb Co |
LAG-3-pozitív tumorok kezelése
|
CA3074565A1
(en)
|
2017-09-05 |
2019-03-14 |
Merck Sharp & Dohme Corp. |
Compounds for reducing the viscosity of biological formulations
|
MX2020009824A
(es)
|
2018-07-25 |
2021-01-15 |
Alteogen Inc |
Nuevas variantes de hialuronidasa y composicion farmaceutica que comprende la misma.
|
US20210317215A1
(en)
|
2018-10-31 |
2021-10-14 |
Merck Sharp & Dohme Corp. |
Anti-human pd-1 antibody crystals and methods of use thereof
|
US20210347889A1
(en)
*
|
2018-11-05 |
2021-11-11 |
Merck Sharp & Dohme Corp. |
Dosing regimen of anti-lag3 antibody and combination therapy with anti-pd-1 antibody for treating cancer
|
JP7503056B6
(ja)
|
2018-11-07 |
2024-07-16 |
メルク・シャープ・アンド・ドーム・エルエルシー |
抗lag3抗体および抗pd-1抗体の共-製剤
|
EP3876978A4
(en)
|
2018-11-07 |
2022-09-28 |
Merck Sharp & Dohme Corp. |
Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
|
BR112023005377A2
(pt)
|
2020-09-24 |
2023-04-25 |
Merck Sharp & Dohme Llc |
Formulações estáveis de anticorpos de receptor de morte programada 1 (pd-1) e variantes de hialuronidase e fragmentos das mesmas e métodos de uso das mesmas
|